Sydney, Australia
Sun 05 10:15
S1.1
Update on Retinopathy—Should We Screen or Not?
Sydney, Australia
Melbourne, Australia
Mon 06 07:30
MTE8.1
Fertility after childhood cancer (assessment, management and associated risks)
Melbourne, Australia
Tue 07 14:00
MTE8.2R
Fertility after childhood cancer (assessment, management and associated risks)
Melbourne, Australia
Curitiba, Brazil
Tue 07 07:45
FC13.2
Pubertal Outcome of 54 Children and Adolescents Treated For Adrenocortical Tumor: A Half of a Century Experience
Curitiba, Brazil
kanpur, India
Tue 07 14:30
FC16.3
Validation of Thyroid Interpreter, a mobile application-based tool in the diagnosis and management of thyroid disorders in childhood
kanpur, India
Mexico city, Mexico
Tue 07 07:45
FC11.2
RIAO as an early biomarker of β-cell failure and predictor biomarker of metabolic syndrome
Mexico city, Mexico
São Paulo, Brazil
Mon 06 08:00
FC4.3
Diagnostic yield of a multigene approach in children with short stature of unknown cause: It is time to remove the term idiopathic!
São Paulo, Brazil
Ribeirao Preto, Brazil
Sun 05 15:15
MTE2.1
Mon 06 14:00
MTE2.2R
Sendai, Japan
Sun 05 10:45
NP1.2
Genotype-based management for Noonan syndrome
Sendai, Japan
Madrid, Spain
Sun 05 10:45
S5.2
Sun 05 15:15
Treatment with recombinant murine Pappa2, GH or IGF-1 modifies hepatic energy metabolism in a mouse model of Pappa2 deficiency
Madrid, Spain
Madrid, Spain
Mon 06 07:30
FC5.1
Evaluation of Clinical Benefit Following Setmelanotide Treatment in Patients With Bardet-Biedl Syndrome
Madrid, Spain
Sydney, NSW, Australia
Sun 05 09:00
PL2
Access to medicines: It’s not "all too hard"! Together we CAN improve access to essential paediatric endocrine medicines for all. A roadmap to 2030.
Sydney, NSW, Australia
USA
Tue 07 10:45
Management of T2D in Youth: Beyond metformin and into The Future.
USA
São Paulo, Brazil
Tue 07 07:30
FC13.1
Retrospective Analysis of Prognostic Factors in Pediatric Patients with Adrenocortical Tumor from Unique Tertiary Center with Long-Term Follow-up
São Paulo, Brazil
France
Sao Paulo, Brazil
Sun 05 10:15
S3.1
Molecular basis and clinical aspects of Androgen Insensitivity Syndrome
Sao Paulo, Brazil
Philadelphia, USA
Mon 06 11:15
S8.3
Current management of children with thyroid cancer
Philadelphia, USA
Denver, United States
Sun 05 10:45
S1.2
Update on Nephropathy—When should we Treat?
Denver, United States
Brazil
Amsterdam, Netherlands
Mon 06 14:45
FC9.4
The dose-dependent effect of estrogen on bone mineral density in trans girls
Amsterdam, Netherlands
Buenos Aires, Argentina
Tue 07 07:30
FC12.1
Does early treatment with recombinant human growth hormone impact in visual assessment?
Buenos Aires, Argentina
Maryland, USA
Paris, France
Tue 07 07:30
FC14.1
Inborn Errors of Protein Metabolism: Longitudinal Data on Growth, Puberty, Bone Mineralisation, and Body Composition
Paris, France
Michigan, USA
Mon 06 10:15
S10.1
Molecular Mechanisms in Congenital Hypopituitarism (Second talk)
Michigan, USA
São Paulo, Brazil
Tue 07 14:00
FC15.1
Update on the etiological diagnosis of central precocious puberty in both sexes
São Paulo, Brazil
CABA, Argentina
Tue 07 14:45
FC16.4
Santiago, Chile
Sun 05 15:30
Dose-dependent Increase in GH AUC0-12h with LUM-201 in Idiopathic Pediatric GH Deficiency (iPGHD) from the Interim Analysis Data of the OraGrowtH212 Trial
Santiago, Chile
Houston, USA
Tue 07 14:00
FC16.1
A Retrospective Analysis of Patients with Pediatric Papillary Thyroid Cancer not Treated with RAI: Is Less More?
Houston, USA
Buenos Aires, Argentina
Sun 05 16:00
FC3.4
The combination of FSH and markers of Sertoli cell function provides a high accuracy strategy to differentiate central hypogonadism from constitutional delay of puberty in boys: a longitudinal prospective study.
Buenos Aires, Argentina
Argentina
Tue 07 10:45
S15.2
Singapore
Tue 07 10:45
S13.2
Odense, Denmark
Sun 05 15:45
FC2.3
EEG changes in children with congenital hyperinsulinism
Odense, Denmark
Nijmegen , The Netherlands
Mon 06 10:15
S9.1
Optimizing treatment in children and adolescents with congenital adrenal hyperplasia
Nijmegen , The Netherlands
Manchester, United Kingdom
Sun 05 16:00
FC2.4
The Arginine-nitric-oxide Pathway Links Suboptimal Fetal Growth to Higher Childhood Systolic Blood Pressure in the Manchester BabyGRO Study
Manchester, United Kingdom
Ghent, Belgium
Sun 05 11:15
S3.3
Clinical approach to DSD: individualised multidisciplinary care
Ghent, Belgium
Buenos Aires, Argentina
Mon 06 11:15
S7.3
Pubertal Tempo in patients with Aromatase Disorders.
Buenos Aires, Argentina
Westmead, Australia
Parkville, Australia
Tue 07 10:15
S13.1
Epigenetics and DOHaD: from basics to birth and beyond.
Parkville, Australia
México, Mexico
Tue 07 14:45
FC17.4
QUANTIFICATION OF LIVER IRON MEASURED BY MAGNETIC RESONANCE IN ADOLESCENTS WITH TYPE 2 DIABETES MELLITUS
México, Mexico
Perth, Australia
Sun 05 10:15
C1.1
Auckland, New Zealand
Mon 06 08:30
PL5
Lucknow, India
Tue 07 11:15
S14.3
Diagnosis and management of Polycystic Ovary Syndrome (PCOS) in India: challenges and opportunities
Lucknow, India
Bern, Switzerland
Mon 06 14:00
FC9.1
Uncovering the role of the SF-1/NR5A1 p.Gly146Ala variant for the phenotype of DSD patients
Bern, Switzerland
Philadelphia, USA
Tue 07 11:15
S12.3
Novel treatments for diazoxide unresponsive congenital hyperinsulinism
Philadelphia, USA
Buenos Aires, Argentina
Tue 07
FC12.3
An in vivo functional assay to characterize human STAT5B genetic variants during zebrafish development
Buenos Aires, Argentina
Seattle, USA
Tue 07 14:15
FC17.2
Diabetes Stigma, Clinical Outcomes, and Substance Use in Adolescents and Young Adults: the SEARCH for Diabetes in Youth Study
Seattle, USA
Cairo, Egypt
Tue 07 08:00
FC11.3
Metformin added to intensive insulin therapy improves Neuregulin-4 level and subclinical atherosclerosis in youth with type 1 diabetes
Cairo, Egypt
Amsterdam, The Netherlands
Tue 07 10:15
S14.1
100 Years after the Discovery of Insulin: Why the Urgent Need to Address Access to Insulin in Low- and Middle-Income Countries?
Amsterdam, The Netherlands
Buenos Aires, Argentina
Mon 06 14:30
FC10.3
Pediatric hypercalcemia in a tertiary center
Buenos Aires, Argentina
Buenos Aires, Argentina
Tue 07 08:15
FC12.4
In vitro funcional characterizationof two novel missense IGF1 variants
Buenos Aires, Argentina
Switzerland
Mon 06 11:15
S9.3
Novel genes leading to congenital hypoadrenalism
Switzerland
Buenos Aires, Argentina
Tue 07 14:45
FC15.4
Growth after discontinuation of GnRHa treatment for idiopathic central precocious puberty (ICPP): an analytical study of 100 Argentinian girls
Buenos Aires, Argentina
Bethesda, USA
Mon 06 07:30
FC7.1
Encaleret (CLTX-305) Normalized Mineral Homeostasis Parameters in Patients with Autosomal Dominant Hypocalcemia Type 1 over 12 months in a Phase 2 Study (NCT04581629)
Bethesda, USA
Illinois, United States
Mon 06 10:45
HDI2.2
Auckland, New Zealand
Tue 07 11:15
S13.3
DOHaD: the challenge of translating the science to policy
Auckland, New Zealand
Austin, USA
Westmead, Australia
Tue 07 08:15
FC13.4
Comparing the single cell transcriptome of wild-type and 21-hydroxylase deficient murine adrenal glands
Westmead, Australia
Aarhus, Denmark
Sun 05 10:15
NP1.1
Cancer risk and co-morbidity in Turner syndrome
Aarhus, Denmark
Buenos Aires, Argentina
Sun 05 10:45
S2.2
FSH-Sertoli cells: a neglected axis in male hypogonadism
Buenos Aires, Argentina
Mexico City, Mexico
Tue 07 08:00
FC14.3
Possible triggers related to the increased frequency of Idiopathic Central Precocious Puberty during and after COVID-19 confinement at the National Institute of Pediatrics in Mexico.
Mexico City, Mexico
Bethesda, USA
Mon 06 08:00
FC7.3
Serum phosphorus levels as a driver of skeletal morbidity in patients with fibrous dysplasia
Bethesda, USA
Istanbul, Turkey
Sun 05 10:45
S3.2
Novel causes and clinical features of primary gonadal failure
Istanbul, Turkey
Amsterdam, The Netherlands
Mon 06 10:15
HDI2.1
How do I provide optimal gender affirming hormone treatment taking into account age-related differences in transgender adolescents?
Amsterdam, The Netherlands
Exeter, UK
Buenos Aires, Argentina
Mon 06 08:15
FC5.4
Hepcidin is associated directly with inflammatory markers and inversely with glucose in Indigenous Argentinean children
Buenos Aires, Argentina
Düsseldorf, Germany
Sun 05 15:15
FC2.1
Increased catecholamines link fetal stress or growth restriction and neonatal hyperinsulinemic hypoglycemia: a prospective cohort study
Düsseldorf, Germany
Ulm, Germany
Tue 07 10:15
Obesity and T2D in Youth: Are they on the rise?
Ulm, Germany
Doha, Qatar
Tue 07 10:15
S12.1
Genotype and phenotype analysis of a cohort of patients with Hypoglycaemia based on DOPA-PET CT scanning
Doha, Qatar
Edinburgh, UK
Sun 05 14:30
PL4
The genetics of extreme short stature: primordial dwarfism, the smallest of the small.
Edinburgh, UK
Bethesda, USA
Mon 06 07:45
FC7.2
São Paulo, Brazil
Sun 05 11:15
S5.3
Clinical and genetic evaluation of children with syndromic short stature
São Paulo, Brazil
Bethesda, USA
Mon 06 08:00
FC6.3
Disruption of Pediatric Cushing Syndrome Evaluations by Heterophile Antibodies interfering with an Adrenocorticotropic Hormone (ACTH) Assay
Bethesda, USA
Copenhagen, Denmark
Lexington, USA
Tue 07 14:30
FC17.3
Pharmacologic inhibition of myostatin with a myostatin antibody protects against muscle and bone loss in an STZ-induced mouse model of type 1 diabetes
Lexington, USA
Ohio, USA
Sun 05 10:15
S5.1
Growth Hormone Action in Growth and Longevity
Ohio, USA
Buenos Aires, Argentina
Tue 07 10:45
NP3.2
The use of GLP-1 receptor co-agonists in paediatrics. Latin American perspective
Buenos Aires, Argentina
Boston, United States
Tue 07 11:15
Novel therapeutics in obesity: Oxytocin
Boston, United States
Paris, France
beijing, China
Tue 07 14:30
FC15.3
The critical BMI hypothesis for puberty initiation and the gender prevalence difference: evidence from an epidemiological survey in Beijing, China
beijing, China
Baltimore, USA
Mon 06 08:15
FC7.4
Growth Hormone and Testosterone Improve Growth, Initiate Puberty, and Protect Against Vertebral Fractures in Children with Muscular Dystrophy on Chronic Glucocorticoids
Baltimore, USA
São Paulo, Brazil
Mon 06 14:15
FC9.2
Self-reported Feelings of Adult Patients with Differences of Sex Development (DSD) Regarding Genital Surgical Procedures
São Paulo, Brazil
Shanghai, China
Tue 07 10:45
S12.2
Efficacy and safety of octreotide treatment for diazoxideunresponsive congenital hyperinsulinism in Chi
Shanghai, China
Stanford, USA
Sun 05 11:15
S1.3
Macrovascular Disease and Risk Factors—Time to be More Aggressive with Treatment?
Stanford, USA
Genova, Italy
Boston, United States
Tue 07 10:15
C2.1
Cerebral salt wasting: Does it exist?
Boston, United States
United States
Mon 06 11:15
HDI2.3
Parental management of cross gender behavior in the prepubertal child, including objections by one or both parents
United States
Buenos Aires, Argentina
Tue 07 15:45
PL12
Genomics and beyond: Protein sequence structure and functional relationships underlying human disease
Buenos Aires, Argentina
Ciudad Autónoma de Buenos Aires, Argentina
Sun 05 16:00
NOVEL INSULIN-LIKE GROWTH FACTOR 1 GENE MUTATION: BROADENING OF THE PHENOTYPE AND IMPLICATIONS FOR INSULIN RESISTANCE
Ciudad Autónoma de Buenos Aires, Argentina
Mon 06 14:15
FC8.2
Overexpression of Brachyury and IGF1R in Thyroid Papillary Carcinoma cells: different phenotypes and asocciation with pediatric Thyroid Nodular Pathology
Ciudad Autónoma de Buenos Aires, Argentina
Paris, France
Sun 05 11:15
S2.3
Novels aspects of replacement therapies in pediatric hypogonadisms
Paris, France
MADRID, Spain
Mon 06 07:45
FC5.2
THE N221D VARIANT IN PCSK1 IS HIGHLY PREVALENT IN CHILDHOOD OBESITY AND CAN INFLUENCE PATIENTS´ METABOLIC PROFILE
MADRID, Spain
Vellore, India
Tue 07 11:15
15.3
Implementing newborn screening for congenital hypothyroidism, where are we? The way forward in developing nations
Vellore, India
Buenos Aires, Argentina
Sun 05 15:15
FC3.1
Characterization and follow-up of a cohort of thirty patients with 46,XX testicular/ovotesticular disorders of sexual development
Buenos Aires, Argentina
Newcastle, UK
Mon 06 11:15
NP2.3
UK
Mon 06 11:15
S10.3
Senescence in pituitary tumours: pathogenic roles and opportunities for novel therapies
UK
Boston, USA
Mon 06 07:30
MTE6.1
Management of endocrine complications of adolescents with functional hypothalamic amenorrhea
Boston, USA
Tue 07 07:30
MTE6.2R
Management of endocrine complications of adolescents with functional hypothalamic amenorrhea
Boston, USA
Pittsburgh, United States
Tue 07 10:45
C2.2
Cerebral salt wasting: Does it exist?
Pittsburgh, United States
Baltimore, United States
Tue 07 10:15
S15.1
X-linked Adrenoleukodystrophy: Newborn Screening, and Therapies
Baltimore, United States
Nagasaki, Japan
Mon 06 14:00
FC10.1
Clinical usefulness of a deep learning-based facial recognition application (Face2Gene) as a diagnostic tool for syndromic endocrine-related disorders.
Nagasaki, Japan
Oldenburg, Germany
Mon 06 10:45
S10.2
Treatment of Hypothalamic Obesity / Craniopharyngioma
Oldenburg, Germany
Brisbane, Australia
Khartoum, Sudan
Tue 07 10:45
S14.2
Allgrove Syndrome: Phenotype-genotype correlation in patients from a resource-limited country
Khartoum, Sudan
San Francisco, USA
Mon 06 07:45
FC4.2
Low-dose infigratinib, an oral selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, demonstrates activity in preclinical models of FGFR3-related disorders
San Francisco, USA
Tokyo, Japan
Mon 06 08:15
FC6.4
Development of a drug screening method for molecular targeted therapy of MIRAGE syndrome
Tokyo, Japan
Cambridge, USA
Mon 06 08:15
FC4.4
Predicted Ratio of IGF-1 Observations and Differences in IGF-1 SDS Observations to 96-hour Values Over the Dosing Interval in Pediatric pGHD Patients Receiving Somatrogon
Cambridge, USA
Botswana , South Africa
Sun 05 15:15
MTE3.1
Diagnosis and Management of Rare Hypophosphataemic Rickets
Botswana , South Africa
Tue 07 07:30
MTE3.2R
Diagnosis and Management of Rare Hypophosphataemic Rickets
Botswana , South Africa
Nairobi, Kenya
Sun 05 08:30
PL1
Paediatric endocrinology training in Sub-Saharan Africa – A 10 year journey from bench to the clinics
Nairobi, Kenya
New York City, USA
Tue 07 14:15
FC16.2
Thyroid Monitoring Trends Following Iodine Exposure during Cardiac Intervention: Practices at a Large Urban Children’s Hospital
New York City, USA
Buenos Aires, Argentina
Mon 06 14:45
FC10.4
Overlapping between dysnaetremias: Ibuprofen, a novel therapeutic key tool to control refractory polyuria – Case series.
Buenos Aires, Argentina
Tokyo, Japan
Sun 05 15:30
FC2.2
Gene expression profile analysis of the Umbilical cord derived mesenchymal stem cells revealed the difference in fetal programming between preterm SGA and term SGA
Tokyo, Japan
Hamamatsu, Japan
Sun 05 15:30
FC3.2
Microdeletion withinESR1 constitutes a worldwide spread susceptibility factor for the development of undermasculinized genitalia
Hamamatsu, Japan
Hamamatsu, Japan
Tue 07 15:15
PL11
Genomic imprinting and its clinical relevance: lessons from Kagami-Ogata syndrome and Temple syndrome
Hamamatsu, Japan
Suita, Japan
Mon 06 14:00
MTE9.1
Bern, Switzerland
Mon 06 07:45
FC6.2
Inhibiting the binding of ACTH to the Melanocorticotropin receptor by peptide to block androgen production.
Bern, Switzerland
Tue 07 07:45
FC12.2
PDE5 inhibitors may reverse the effects of isolated growth hormone deficiency caused by alternate splicing of the GH1 gene.
Bern, Switzerland
Buenos Aires, Argentina
Mon 06 10:15
S8.1
Workup of children with thyroid nodules
Buenos Aires, Argentina
Messina, Italy
Mon 06 14:30
FC8.3
Sensitivity to thyroid hormones and cardiometabolic risk in euthyroid obese children: a cross-sectional study.
Messina, Italy
Los Angeles, USA
Mon 06 07:30
FC4.1
Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: results from an ongoing Phase 3 extension study
Los Angeles, USA
London, UK
Mon 06 10:45
NP2.2
Kanpur, India
Sun 05 15:45
FC3.3
DSD Interpreter, a mobile application-based tool for Point of Care evaluation of Atypical Genitalia.
Kanpur, India
Helsinki, Finland
Mon 06 10:15
S7.1
CABA, Argentina
Mon 06 14:45
FC8.4
Custom next generation sequencing panel identifies somatic mutations and gene fusions in pediatric papillary thyroid carcinoma
CABA, Argentina
Sao Paulo, Brazil
Tue 07 14:15
FC15.2
Several new candidate genes for self-limited delayed puberty revealed by whole exome sequencing
Sao Paulo, Brazil
Toronto, Canada
Mon 06 11:15
S6.3
Exercise in T1D in Youth: More relevant than ever in the era of obesity?
Toronto, Canada
Buenos Aires, Argentina
Tue 07 08:15
FC14.4
Pituitary Gigantism: Argentine experience
Buenos Aires, Argentina
Santiago, Chile
Tue 07 08:00
FC13.3
Differential methylation of CYP11B1 in girls with high DHEAS levels
Santiago, Chile
Bern, Switzerland
Mon 06 14:30
FC9.3
Mutation V631I in the Cytochrome P450 oxidoreductase (POR) alters steroid biosynthesis and drug metabolism.
Bern, Switzerland
Seattle, USA
Mon 06 08.00
FC5.3
Development of Novel Anorexigenic and Glucoregulatory Chimeric Peptides
Seattle, USA
Stockholm, Sweden
Mon 06 11:15
EP1.3
Sioux Falls, USA
Tue 07 14:00
FC17.1
T regulatory cells with engineered chimeric antigen receptor recognizing live human beta cells as a novel tool for development of type 1 diabetes therapies.
Sioux Falls, USA
Geneva, Switzerland
Tue 07 08:15
FC11.4
Meal-induced activation of inflammatory pathways in youth with monogenic diabetes revealed by transcriptome analysis
Geneva, Switzerland
fuzhou, China
Tue 07 07:45
FC14.2
KMT2D deficiency in vertebrates: Identification of a novel human mutation and generation of a zebrafish model
fuzhou, China
Bern, Switzerland
Mon 06 14:15
FC10.2
Targeting androgen production by post-translational regulation of CYP17A1 lyase activity.
Bern, Switzerland
Conneticut, United States
Mon 06 10:15
S6.1
Insulin therapy: From MDI to artificial pancreas
Conneticut, United States
Japan
Toronto, Canada
Sun 05 10:15
HD1.1
Melbourne, Australia
Tue 07 11:15
S11.3
Bisphosphonate therapy in children: who benefits, treatment duration, which preparation
Melbourne, Australia
Newcastle, Australia
Mon 06 10:45
S6.2
Macronutrients management in T1D in Youth
Newcastle, Australia
North Adelaide, Australia
Tue 07 07:30
FC11.1
Adolescents with type 2 diabetes experience significant diabetes-specific distress, poor emotional wellbeing and have unmet needs hindering optimal diabetes care
North Adelaide, Australia
Shimotsuke, Japan
Mon 06 10:45
S9.2
New perspectives for neonatal screening for CAH
Shimotsuke, Japan
Córdoba, Spain
Sun 05 10:15
S2.1
Metabolic dysfunction in polycystic ovary syndrome and pathogenic role of androgen excess
Córdoba, Spain
Australia
Mon 06 10:15
NP2.1
Genetics of mitochondrial diseases: when the nucleus talks to the mitochondrion
Australia
New York, USA
Sun 05 15:15
MTE4.1
Diagnosis and management of congenital hypothyroidism under different socioeconomic contexts
New York, USA
Tue 07 07:30
MTE4.2R
Diagnosis and management of congenital hypothyroidism under different socioeconomic contexts
New York, USA
Salzburg, Austria
Tue 07 10:15
NP3.1
GLP1-RA use in adolescent obesity
Salzburg, Austria
Minneapolis, USA
Mon 06 07:30
FC6.1
Anastrozole improves height outcomes in growing children with congenital adrenal hyperplasia
Minneapolis, USA
Bethesda, USA
Tue 07 10:15
S11.1
Advances in the Management of Hypoparathyroidism with PTH 1-34
Bethesda, USA
Fukushima, Japan
Mon 06 10:45
S8.2
Lessons from Fukushima: Current situation of Thyroid Cancer among children and adolescents after the Fukushima Daiichi Nuclear Power Plant accident
Fukushima, Japan
Buenos Aires, Argentina
Tue 07 10:45
S11.2
Aurora, Colorado, United States
Sun 05 10:45
C1.2
FOR
Aurora, Colorado, United States
Zhejiang, China
Tue 07 09:15
PL10
Glial regulation of energy metabolism: diet-induced metabolic inflammation shapes feeding circuitry during development
Zhejiang, China
Ciudad Autónoma de Buenos Aires, Argentina
Sun 05 15:45
FC1.3
AGE-DEPENDENT AND SEX-SPECIFIC CHANGES OF DNA METHYLATION WITHIN GROWTH HORMONE RECEPTOR (GHR), INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF1R) AND INSULIN RECEPTOR (INSR) GENE PROMOTERS IN PERIPHERAL BLOOD LEUKOCYTES FROM HEALTHY PREPUBERTAL AND PUBERTAL CHILDREN
Ciudad Autónoma de Buenos Aires, Argentina
Workshop
0
Oral
0
Expert
16
Plenary
12
Catering and Social
7
Nurse
0
Other
0
Symposium
13
No Session Type
29
Sun 05 15:15
MTE2.1
Sun 05 15:15
MTE3.1
Diagnosis and Management of Rare Hypophosphataemic Rickets
Botswana , South Africa
Sun 05 15:15
MTE4.1
Diagnosis and management of congenital hypothyroidism under different socioeconomic contexts
New York, USA
Mon 06 07:30
MTE6.1
Management of endocrine complications of adolescents with functional hypothalamic amenorrhea
Boston, USA
Mon 06 07:30
MTE8.1
Fertility after childhood cancer (assessment, management and associated risks)
Melbourne, Australia
Mon 06 14:00
MTE9.1
Mon 06 14:00
MTE2.2R
Tue 07 07:30
MTE3.2R
Diagnosis and Management of Rare Hypophosphataemic Rickets
Botswana , South Africa
Tue 07 07:30
MTE4.2R
Diagnosis and management of congenital hypothyroidism under different socioeconomic contexts
New York, USA
Tue 07 07:30
MTE6.2R
Management of endocrine complications of adolescents with functional hypothalamic amenorrhea
Boston, USA
Tue 07 14:00
MTE8.2R
Fertility after childhood cancer (assessment, management and associated risks)
Melbourne, Australia
Sun 05 08:30
PL1
Paediatric endocrinology training in Sub-Saharan Africa – A 10 year journey from bench to the clinics
Nairobi, Kenya
Sun 05 09:00
PL2
Access to medicines: It’s not "all too hard"! Together we CAN improve access to essential paediatric endocrine medicines for all. A roadmap to 2030.
Sydney, NSW, Australia
Sun 05 14:30
PL4
The genetics of extreme short stature: primordial dwarfism, the smallest of the small.
Edinburgh, UK
Mon 06 08:30
PL5
Tue 07 09:15
PL10
Glial regulation of energy metabolism: diet-induced metabolic inflammation shapes feeding circuitry during development
Zhejiang, China
Tue 07 15:15
PL11
Genomic imprinting and its clinical relevance: lessons from Kagami-Ogata syndrome and Temple syndrome
Hamamatsu, Japan
Tue 07 15:45
PL12
Genomics and beyond: Protein sequence structure and functional relationships underlying human disease
Buenos Aires, Argentina
Sun 05 10:15
S1.1
Update on Retinopathy—Should We Screen or Not?
Sydney, Australia
Sun 05 10:45
S1.2
Update on Nephropathy—When should we Treat?
Denver, United States
Sun 05 11:15
S1.3
Macrovascular Disease and Risk Factors—Time to be More Aggressive with Treatment?
Stanford, USA
Sun 05 10:15
S2.1
Metabolic dysfunction in polycystic ovary syndrome and pathogenic role of androgen excess
Córdoba, Spain
Sun 05 10:45
S2.2
FSH-Sertoli cells: a neglected axis in male hypogonadism
Buenos Aires, Argentina
Sun 05 11:15
S2.3
Novels aspects of replacement therapies in pediatric hypogonadisms
Paris, France
Sun 05 10:15
S3.1
Molecular basis and clinical aspects of Androgen Insensitivity Syndrome
Sao Paulo, Brazil
Sun 05 10:45
S3.2
Novel causes and clinical features of primary gonadal failure
Istanbul, Turkey
Sun 05 11:15
S3.3
Clinical approach to DSD: individualised multidisciplinary care
Ghent, Belgium
Sun 05 10:15
S5.1
Growth Hormone Action in Growth and Longevity
Ohio, USA
Sun 05 10:45
S5.2
Sun 05 11:15
S5.3
Clinical and genetic evaluation of children with syndromic short stature
São Paulo, Brazil
Mon 06 10:15
S6.1
Insulin therapy: From MDI to artificial pancreas
Conneticut, United States
Mon 06 10:45
S6.2
Macronutrients management in T1D in Youth
Newcastle, Australia
Mon 06 11:15
S6.3
Exercise in T1D in Youth: More relevant than ever in the era of obesity?
Toronto, Canada
Mon 06 10:15
S7.1
Mon 06 11:15
S7.3
Pubertal Tempo in patients with Aromatase Disorders.
Buenos Aires, Argentina
Mon 06 10:15
S8.1
Workup of children with thyroid nodules
Buenos Aires, Argentina
Mon 06 10:45
S8.2
Lessons from Fukushima: Current situation of Thyroid Cancer among children and adolescents after the Fukushima Daiichi Nuclear Power Plant accident
Fukushima, Japan
Mon 06 11:15
S8.3
Current management of children with thyroid cancer
Philadelphia, USA
Mon 06 10:15
S9.1
Optimizing treatment in children and adolescents with congenital adrenal hyperplasia
Nijmegen , The Netherlands
Mon 06 10:45
S9.2
New perspectives for neonatal screening for CAH
Shimotsuke, Japan
Mon 06 11:15
S9.3
Novel genes leading to congenital hypoadrenalism
Switzerland
Mon 06 10:15
S10.1
Molecular Mechanisms in Congenital Hypopituitarism (Second talk)
Michigan, USA
Mon 06 10:45
S10.2
Treatment of Hypothalamic Obesity / Craniopharyngioma
Oldenburg, Germany
Mon 06 11:15
S10.3
Senescence in pituitary tumours: pathogenic roles and opportunities for novel therapies
UK
Tue 07 10:15
Obesity and T2D in Youth: Are they on the rise?
Ulm, Germany
Tue 07 10:45
Management of T2D in Youth: Beyond metformin and into The Future.
USA
Tue 07 11:15
Novel therapeutics in obesity: Oxytocin
Boston, United States
Tue 07 10:15
S11.1
Advances in the Management of Hypoparathyroidism with PTH 1-34
Bethesda, USA
Tue 07 10:45
S11.2
Tue 07 11:15
S11.3
Bisphosphonate therapy in children: who benefits, treatment duration, which preparation
Melbourne, Australia
Tue 07 10:15
S12.1
Genotype and phenotype analysis of a cohort of patients with Hypoglycaemia based on DOPA-PET CT scanning
Doha, Qatar
Tue 07 10:45
S12.2
Efficacy and safety of octreotide treatment for diazoxideunresponsive congenital hyperinsulinism in Chi
Shanghai, China
Tue 07 11:15
S12.3
Novel treatments for diazoxide unresponsive congenital hyperinsulinism
Philadelphia, USA
Tue 07 10:15
S15.1
X-linked Adrenoleukodystrophy: Newborn Screening, and Therapies
Baltimore, United States
Tue 07 10:45
S15.2
Tue 07 11:15
15.3
Implementing newborn screening for congenital hypothyroidism, where are we? The way forward in developing nations
Vellore, India
Sun 05 15:15
FC2.1
Increased catecholamines link fetal stress or growth restriction and neonatal hyperinsulinemic hypoglycemia: a prospective cohort study
Düsseldorf, Germany
Sun 05 15:30
FC2.2
Gene expression profile analysis of the Umbilical cord derived mesenchymal stem cells revealed the difference in fetal programming between preterm SGA and term SGA
Tokyo, Japan
Sun 05 15:45
FC2.3
EEG changes in children with congenital hyperinsulinism
Odense, Denmark
Sun 05 16:00
FC2.4
The Arginine-nitric-oxide Pathway Links Suboptimal Fetal Growth to Higher Childhood Systolic Blood Pressure in the Manchester BabyGRO Study
Manchester, United Kingdom
Sun 05 15:15
FC3.1
Characterization and follow-up of a cohort of thirty patients with 46,XX testicular/ovotesticular disorders of sexual development
Buenos Aires, Argentina
Sun 05 15:30
FC3.2
Microdeletion withinESR1 constitutes a worldwide spread susceptibility factor for the development of undermasculinized genitalia
Hamamatsu, Japan
Sun 05 15:45
FC3.3
DSD Interpreter, a mobile application-based tool for Point of Care evaluation of Atypical Genitalia.
Kanpur, India
Sun 05 16:00
FC3.4
The combination of FSH and markers of Sertoli cell function provides a high accuracy strategy to differentiate central hypogonadism from constitutional delay of puberty in boys: a longitudinal prospective study.
Buenos Aires, Argentina
Mon 06 07:30
FC4.1
Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: results from an ongoing Phase 3 extension study
Los Angeles, USA
Mon 06 07:45
FC4.2
Low-dose infigratinib, an oral selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, demonstrates activity in preclinical models of FGFR3-related disorders
San Francisco, USA
Mon 06 08:00
FC4.3
Diagnostic yield of a multigene approach in children with short stature of unknown cause: It is time to remove the term idiopathic!
São Paulo, Brazil
Mon 06 08:15
FC4.4
Predicted Ratio of IGF-1 Observations and Differences in IGF-1 SDS Observations to 96-hour Values Over the Dosing Interval in Pediatric pGHD Patients Receiving Somatrogon
Cambridge, USA
Mon 06 07:30
FC5.1
Evaluation of Clinical Benefit Following Setmelanotide Treatment in Patients With Bardet-Biedl Syndrome
Madrid, Spain
Mon 06 07:45
FC5.2
THE N221D VARIANT IN PCSK1 IS HIGHLY PREVALENT IN CHILDHOOD OBESITY AND CAN INFLUENCE PATIENTS´ METABOLIC PROFILE
MADRID, Spain
Mon 06 08.00
FC5.3
Development of Novel Anorexigenic and Glucoregulatory Chimeric Peptides
Seattle, USA
Mon 06 08:15
FC5.4
Hepcidin is associated directly with inflammatory markers and inversely with glucose in Indigenous Argentinean children
Buenos Aires, Argentina
Mon 06 07:30
FC6.1
Anastrozole improves height outcomes in growing children with congenital adrenal hyperplasia
Minneapolis, USA
Mon 06 07:45
FC6.2
Inhibiting the binding of ACTH to the Melanocorticotropin receptor by peptide to block androgen production.
Bern, Switzerland
Mon 06 08:00
FC6.3
Disruption of Pediatric Cushing Syndrome Evaluations by Heterophile Antibodies interfering with an Adrenocorticotropic Hormone (ACTH) Assay
Bethesda, USA
Mon 06 08:15
FC6.4
Development of a drug screening method for molecular targeted therapy of MIRAGE syndrome
Tokyo, Japan
Mon 06 07:30
FC7.1
Encaleret (CLTX-305) Normalized Mineral Homeostasis Parameters in Patients with Autosomal Dominant Hypocalcemia Type 1 over 12 months in a Phase 2 Study (NCT04581629)
Bethesda, USA
Mon 06 07:45
FC7.2
Mon 06 08:00
FC7.3
Serum phosphorus levels as a driver of skeletal morbidity in patients with fibrous dysplasia
Bethesda, USA
Mon 06 08:15
FC7.4
Growth Hormone and Testosterone Improve Growth, Initiate Puberty, and Protect Against Vertebral Fractures in Children with Muscular Dystrophy on Chronic Glucocorticoids
Baltimore, USA
Mon 06 14:15
FC8.2
Overexpression of Brachyury and IGF1R in Thyroid Papillary Carcinoma cells: different phenotypes and asocciation with pediatric Thyroid Nodular Pathology
Ciudad Autónoma de Buenos Aires, Argentina
Mon 06 14:30
FC8.3
Sensitivity to thyroid hormones and cardiometabolic risk in euthyroid obese children: a cross-sectional study.
Messina, Italy
Mon 06 14:45
FC8.4
Custom next generation sequencing panel identifies somatic mutations and gene fusions in pediatric papillary thyroid carcinoma
CABA, Argentina
Mon 06 14:00
FC9.1
Uncovering the role of the SF-1/NR5A1 p.Gly146Ala variant for the phenotype of DSD patients
Bern, Switzerland
Mon 06 14:15
FC9.2
Self-reported Feelings of Adult Patients with Differences of Sex Development (DSD) Regarding Genital Surgical Procedures
São Paulo, Brazil
Mon 06 14:30
FC9.3
Mutation V631I in the Cytochrome P450 oxidoreductase (POR) alters steroid biosynthesis and drug metabolism.
Bern, Switzerland
Mon 06 14:45
FC9.4
The dose-dependent effect of estrogen on bone mineral density in trans girls
Amsterdam, Netherlands
Mon 06 14:00
FC10.1
Clinical usefulness of a deep learning-based facial recognition application (Face2Gene) as a diagnostic tool for syndromic endocrine-related disorders.
Nagasaki, Japan
Mon 06 14:15
FC10.2
Targeting androgen production by post-translational regulation of CYP17A1 lyase activity.
Bern, Switzerland
Mon 06 14:30
FC10.3
Pediatric hypercalcemia in a tertiary center
Buenos Aires, Argentina
Mon 06 14:45
FC10.4
Overlapping between dysnaetremias: Ibuprofen, a novel therapeutic key tool to control refractory polyuria – Case series.
Buenos Aires, Argentina
Tue 07 07:30
FC11.1
Adolescents with type 2 diabetes experience significant diabetes-specific distress, poor emotional wellbeing and have unmet needs hindering optimal diabetes care
North Adelaide, Australia
Tue 07 07:45
FC11.2
RIAO as an early biomarker of β-cell failure and predictor biomarker of metabolic syndrome
Mexico city, Mexico
Tue 07 08:00
FC11.3
Metformin added to intensive insulin therapy improves Neuregulin-4 level and subclinical atherosclerosis in youth with type 1 diabetes
Cairo, Egypt
Tue 07 08:15
FC11.4
Meal-induced activation of inflammatory pathways in youth with monogenic diabetes revealed by transcriptome analysis
Geneva, Switzerland
Tue 07 07:30
FC12.1
Does early treatment with recombinant human growth hormone impact in visual assessment?
Buenos Aires, Argentina
Tue 07 07:45
FC12.2
PDE5 inhibitors may reverse the effects of isolated growth hormone deficiency caused by alternate splicing of the GH1 gene.
Bern, Switzerland
Tue 07
FC12.3
An in vivo functional assay to characterize human STAT5B genetic variants during zebrafish development
Buenos Aires, Argentina
Tue 07 08:15
FC12.4
In vitro funcional characterizationof two novel missense IGF1 variants
Buenos Aires, Argentina
Tue 07 07:30
FC13.1
Retrospective Analysis of Prognostic Factors in Pediatric Patients with Adrenocortical Tumor from Unique Tertiary Center with Long-Term Follow-up
São Paulo, Brazil
Tue 07 07:45
FC13.2
Pubertal Outcome of 54 Children and Adolescents Treated For Adrenocortical Tumor: A Half of a Century Experience
Curitiba, Brazil
Tue 07 08:00
FC13.3
Differential methylation of CYP11B1 in girls with high DHEAS levels
Santiago, Chile
Tue 07 08:15
FC13.4
Comparing the single cell transcriptome of wild-type and 21-hydroxylase deficient murine adrenal glands
Westmead, Australia
Tue 07 07:30
FC14.1
Inborn Errors of Protein Metabolism: Longitudinal Data on Growth, Puberty, Bone Mineralisation, and Body Composition
Paris, France
Tue 07 07:45
FC14.2
KMT2D deficiency in vertebrates: Identification of a novel human mutation and generation of a zebrafish model
fuzhou, China
Tue 07 08:00
FC14.3
Possible triggers related to the increased frequency of Idiopathic Central Precocious Puberty during and after COVID-19 confinement at the National Institute of Pediatrics in Mexico.
Mexico City, Mexico
Tue 07 08:15
FC14.4
Pituitary Gigantism: Argentine experience
Buenos Aires, Argentina
Tue 07 14:00
FC15.1
Update on the etiological diagnosis of central precocious puberty in both sexes
São Paulo, Brazil
Tue 07 14:15
FC15.2
Several new candidate genes for self-limited delayed puberty revealed by whole exome sequencing
Sao Paulo, Brazil
Tue 07 14:30
FC15.3
The critical BMI hypothesis for puberty initiation and the gender prevalence difference: evidence from an epidemiological survey in Beijing, China
beijing, China
Tue 07 14:45
FC15.4
Growth after discontinuation of GnRHa treatment for idiopathic central precocious puberty (ICPP): an analytical study of 100 Argentinian girls
Buenos Aires, Argentina
Tue 07 14:00
FC16.1
A Retrospective Analysis of Patients with Pediatric Papillary Thyroid Cancer not Treated with RAI: Is Less More?
Houston, USA
Tue 07 14:15
FC16.2
Thyroid Monitoring Trends Following Iodine Exposure during Cardiac Intervention: Practices at a Large Urban Children’s Hospital
New York City, USA
Tue 07 14:30
FC16.3
Validation of Thyroid Interpreter, a mobile application-based tool in the diagnosis and management of thyroid disorders in childhood
kanpur, India
Tue 07 14:45
FC16.4
Tue 07 14:00
FC17.1
T regulatory cells with engineered chimeric antigen receptor recognizing live human beta cells as a novel tool for development of type 1 diabetes therapies.
Sioux Falls, USA
Tue 07 14:15
FC17.2
Diabetes Stigma, Clinical Outcomes, and Substance Use in Adolescents and Young Adults: the SEARCH for Diabetes in Youth Study
Seattle, USA
Tue 07 14:30
FC17.3
Pharmacologic inhibition of myostatin with a myostatin antibody protects against muscle and bone loss in an STZ-induced mouse model of type 1 diabetes
Lexington, USA
Tue 07 14:45
FC17.4
QUANTIFICATION OF LIVER IRON MEASURED BY MAGNETIC RESONANCE IN ADOLESCENTS WITH TYPE 2 DIABETES MELLITUS
México, Mexico
0 result(s) found.